Updated financial estimates workbook

5 July - An updated version of the Utilisation and cost model workbook is now available to support PBAC Submission. ...

Read more →

New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions

18 January 2019 - A new whitepaper authored by Bruce Pyenson and colleagues from Milliman explains why ICER potential budget ...

Read more →

The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges

20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000.  ...

Read more →

Pharmaceutical Benefits Advisory Committee recommendations in Australia

16 December 2017 - The aim of this study was to examine submissions made to the PBAC and assess whether the ...

Read more →

Obesity related diseases expected to cost Australia $21 billion

11 October 2017 - Without action on obesity, the economic burden of treating obesity related diseases is estimated to rise from ...

Read more →

Final budget outcomes reveal industry efforts to take pressure off PBS

26 September 2017 - The Final Budget Outcome papers released today reveal the enormous efforts of the members of Medicines ...

Read more →

ABPI applies for Judicial Review over new procedures that restrict access to cost-effective medicines

10 July 2017 - Following a story published today in the Financial Times, the Association of the British Pharmaceutical Industry ...

Read more →

New budget test puts UK on front line in global drug price fight

27 March 2017 - Can society afford modern medicines? It's a question facing governments worldwide and nowhere more so than ...

Read more →

Drug cost-saving plans may hit patients

19 January 2017 - Patients in England may face delays getting new drugs or go without them if NHS bosses ...

Read more →

Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months

5 December 2016 - Hepatitis C medications approved in March this year have already topped the list of Australia's most ...

Read more →

Amgen eyes spending caps to win payer nods on migraine prospect erenumab

21 November 2016 - Note to drugmakers negotiating with payers: it’s not the price tag that’s the problem, or at ...

Read more →

Budget criteria and drug value assessments: a case of apples and oranges?

22 September 2016 - Last year, the US Department of Health and Human Services announced a historic initiative to shift Medicare’s ...

Read more →

Value: can we afford to think long-term while ignoring budget impact?

22 September 2016 - Steve Pearson from ICER reponds to a recent Health Affairs Blog post by 2 academics.  ...

Read more →

Antihaemophilic factor (recombinant BDD) Fc fusion protein (Eloctate): treatment cost comparison and budget impact analysis

9 November 2015 - CADTH's final science report is now available for the project on antihaemophilic factor (recombinant BDD) Fc fusion ...

Read more →

Coagulation factor IX FC fusion protein (Alprolix): treatment cost comparison and budget impact analysis

9 November 2015 - CADTH's final science report is now available for the project on coagulation factor IX FC fusion protein ...

Read more →